Ventyx Biosciences to Host R&D Event on January 26, 2023

Rhea-AI Summary

Ventyx Biosciences, a clinical-stage biopharmaceutical company, will host an R&D event on January 26, 2023, in New York City from 9-11:30 a.m. ET. Key executives, including CEO Raju Mohan and CMO William Sandborn, will present insights into the company's clinical-stage and discovery programs focused on oral therapies for inflammatory diseases. The event will be available for live streaming on their website, with a replay to follow. Ventyx aims to innovate in immunology by shifting from injectable to oral medications.

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET. The event will highlight key aspects of Ventyx’s clinical-stage and discovery programs.

Participating in the presentations and discussions will be members of the Ventyx Executive Team and Clinical Advisors, including:

• Raju Mohan, PhD, Founder, Chief Executive Officer and Director
• William Sandborn, MD, President and Chief Medical Officer
• John Nuss, PhD, Chief Scientific Officer
• James Krueger, MD, PhD, Director of the Milstein Medical Research Program and D. Martin Carter Professor in Clinical Investigation at Rockefeller University in New York

A live webcast of the event will be available in the “Investors” section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

FAQ

What is the date and location of Ventyx Biosciences' R&D event?

The R&D event will take place on January 26, 2023, in New York City.

Who will present at the Ventyx R&D event?

Key executives including Raju Mohan, William Sandborn, and John Nuss will present at the event.

Where can I watch the Ventyx R&D event?

The event will be live streamed on Ventyx's website in the Investors section.

What is the focus of Ventyx Biosciences?

Ventyx focuses on developing novel oral therapies for autoimmune and inflammatory diseases.

What are the candidates in Ventyx's pipeline?

Ventyx's pipeline includes programs targeting TYK2, S1P1R, and NLRP3.

What time will the Ventyx event start?

The event is scheduled to start at 9:00 a.m. ET on January 26, 2023.